🏛️ Verified NIH Record • Updated 2026-04-22
Predicting Effective Therapy in Pancreatic Cancer (NCT03033927)
Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Memorial Sloan Kettering Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
- CTC isolocation and analysis (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer
- A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
- Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
- Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland
Explore by condition: All Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.